Zacks Research Equities Analysts Cut Earnings Estimates for Amarin Co. plc (NASDAQ:AMRN)

Amarin Co. plc (NASDAQ:AMRN) – Stock analysts at Zacks Research reduced their Q3 2025 earnings per share estimates for shares of Amarin in a report issued on Wednesday, June 26th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings per share of ($0.06) for the quarter, down from their prior estimate of ($0.05). The consensus estimate for Amarin’s current full-year earnings is ($0.18) per share. Zacks Research also issued estimates for Amarin’s Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.24) EPS and FY2026 earnings at ($0.14) EPS.

Several other research firms also recently commented on AMRN. Cantor Fitzgerald restated an “overweight” rating on shares of Amarin in a report on Tuesday, June 18th. StockNews.com downgraded Amarin from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, Amarin has an average rating of “Hold” and an average price target of $1.08.

Amarin Stock Up 2.8 %

AMRN opened at $0.71 on Monday. The stock’s fifty day moving average is $0.81 and its two-hundred day moving average is $0.95. The company has a market capitalization of $289.52 million, a P/E ratio of -5.88 and a beta of 1.95. Amarin has a 52 week low of $0.63 and a 52 week high of $1.49.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.02. Amarin had a negative return on equity of 9.48% and a negative net margin of 18.96%. The firm had revenue of $56.52 million during the quarter, compared to analyst estimates of $51.34 million. During the same period last year, the company earned ($0.04) EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Axxcess Wealth Management LLC boosted its position in shares of Amarin by 4.5% in the 3rd quarter. Axxcess Wealth Management LLC now owns 1,274,283 shares of the biopharmaceutical company’s stock worth $1,172,000 after purchasing an additional 54,955 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Amarin by 351.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 44,599 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 34,725 shares in the last quarter. SVB Wealth LLC boosted its position in shares of Amarin by 100.0% in the 4th quarter. SVB Wealth LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 30,000 shares in the last quarter. Waterfront Wealth Inc. boosted its position in shares of Amarin by 18.0% in the 4th quarter. Waterfront Wealth Inc. now owns 386,735 shares of the biopharmaceutical company’s stock worth $336,000 after purchasing an additional 58,942 shares in the last quarter. Finally, Gilliland Jeter Wealth Management LLC acquired a new stake in shares of Amarin in the 4th quarter worth $64,000. 22.25% of the stock is currently owned by hedge funds and other institutional investors.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.